Navigation Links
Newer Drug-Releasing Stent Cuts Chances of Cardiac Events: Study
Date:8/21/2012

TUESDAY, Aug. 21 (HealthDay News) -- A newer generation, drug-releasing stent led to fewer adverse cardiac events, such as heart-related death or heart attack linked to the same artery, than bare metal stents did among heart attack patients, a new study shows.

Stents are tiny mesh tubes surgically implanted to open arteries.

Swiss researchers noted the newer drug-emitting stents may also help patients avoid the chronic inflammation associated with early-generation drug-releasing stents.

"Newer-generation drug-eluting stents with biodegradable polymers provide controlled drug release," the study authors explained in the Aug. 22/29 issue of the Journal of the American Medical Association.

Led by Dr. Lorenz Raber, of Bern University Hospital, the research team compared the safety and effectiveness of stents that released the drug biolimus from a biodegradable polymer, against bare metal stents that did not release a drug.

The study involved almost 1,200 patients in Europe and Israel who had a type of heart attack known as ST-segment elevation myocardial infarction (STEMI). Nearly 80 percent of the patients were men, and the average age was 61 years.

The participants were randomly assigned to receive the drug-releasing stent or the bare metal stent. They were examined one month after their artery opening procedure, and again at 12 months. The researchers determined the effectiveness of the stents by measuring rates of adverse cardiac events, including cardiac death and other heart problems.

The investigators found that at one year, 4.3 percent of patients who received the drug-releasing stents experienced major adverse cardiac events, compared to 8.7 percent of patients who received bare metal stents.

These findings represent a significant 4.4 percent absolute reduction and 51 percent relative reduction in the risk for major adverse cardiac events, the researchers pointed out in a journal news release.

Use of the new drug-releasing stent also resulted in reduced risk for cardiac death. At one year, rates of clotting within the stent were about 1 percent among patients with the drug-releasing stents, compared to just over 2 percent among patients who received bare metal stents.

"Our results suggest better clinical outcomes in terms of major adverse cardiac events of a stent releasing biolimus from a biodegradable polymer compared with a bare metal stent for the treatment of patients with STEMI," the study authors concluded.

Another expert agreed.

"Newer generation drug-eluting stents which are currently FDA-approved in the United States have been shown to be superior to bare metal stents in decreasing event rates at one year when used for [heart attack]," said Dr. Barry Kaplan, vice chairman of cardiology at North Shore University Hospital in Manhasset, N.Y. "This trial is further proof that drug-eluting stents used in heart attack patients lead to superior results," he added.

And Kaplan noted that, compared to bare metal stents, the drug-releasing models had fewer dangerous events at one year, including re-closure of the artery or clotting within the stent.

But, he added one caveat.

"The relative comparison between the biolimus-coated stent used in this study versus [other] currently available second-generation drug-eluting stents [available in the United States] still needs to be determined," Kaplan said.

More information

The U.S. National Library of Medicine has more about stents.

-- Mary Elizabeth Dallas

SOURCES: Barry Kaplan, M.D., F.A.C.C., vice chairman, cardiology, North Shore University Hospital, Manhasset, N.Y., and Long Island Jewish Medical Center, New Hyde Park, N.Y.; Journal of the American Medical Association, news release, Aug. 21, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Newer Antidepressants May Be Safe for Parkinsons Patients
2. Newer Second-Line Diabetes Drug May Outperform Older Meds
3. Law Firm Aggressively Litigating against Birth Control Makers for their Newer, but Allegedly Unsafer Products: Nuvaring, Yaz, BeYaz, Yasmin, Ocella, Gianvi
4. Newer technology to control blood sugar works better than conventional methods
5. Newer hip reconstruction technique provides good outcomes for athletes
6. Newer Bone Drug Better for Advanced Breast Cancer Patients: Study
7. Older Antipsychotics May Work as Well as Newer Ones: Review
8. Newer Psoriasis Drugs May Lower Heart Attack Risk for Patients
9. Dissolvable Heart Artery Stents Appear Safe in Study
10. Life-saving primary PCI rising in Stent for Life countries
11. Baseline characteristics of children with mild persistent asthma predict response to ICS
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newer Drug-Releasing Stent Cuts Chances of Cardiac Events: Study
(Date:8/22/2017)... ... August 22, 2017 , ... John ... Founder and Managing Member for t4 Leadership Development & Consulting. He has spent ... definition of “success”: physician leadership development, servant leadership, data driven process improvement, and ...
(Date:8/21/2017)... ... August 22, 2017 , ... Nanoparticle research ... health and safety. By learning and implementing best practices for containment using ventilated ... webinar, attendees will gain a better understanding of a method for safely testing ...
(Date:8/21/2017)... ... August 21, 2017 , ... Five chefs from local senior assisted living ... Center. , Guests will be able to vote for their favorite Chef among ... with Fennel Dill Salad, Feta Cheese Sauce & Garlic Pita Crisp, Greek Mountain Ice ...
(Date:8/21/2017)... ... August 21, 2017 , ... The American Hospital Association ... (AHN), a Highmark Health company, to its Board of Trustees for a three-year term ... of health care provider organizations and individuals that are committed to the improvement of ...
(Date:8/20/2017)... ... August 20, 2017 , ... ... ComplyPAK™ Compliance Management System has assisted multiple clients in successfully passing audits ... Service Organization Control Level 2 (AICPA SOC Level 2), and State Data Use ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) today ... effective Aug. 7, 2017. ... interests and will serve as president emeritus during a planned, ... in multiple leadership roles since he joined Diplomat with the ... provided decisive, strategic leadership which continues to benefit our patients ...
(Date:8/3/2017)...  Opioid addiction and other drugs of abuse, blood ... threatening outcomes, were problems taken on directly as laboratory ... support them, met this week. This according to Kalorama ... of abuse, procalcitonin and acute kidney injury were key ... meeting in San Diego, CA. ...
(Date:8/1/2017)... CerSci Therapeutics , a non-opioid drug development firm based ... notice from the National Institute on Drug Abuse (NIDA) ... has been awarded a Direct-to-Phase II Small Business Innovation ... an additional $1,000,000 to follow in 2018. These funds ... lead non-opioid drug candidate CT-044 to the Food and ...
Breaking Medicine Technology: